• Press Release

BIA responds to 2021 Budget

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA), said: "The COVID-19 pandemic has shown the strategic necessity for the UK to have a thriving domestic life sciences and biotech sector. Companies and researchers from across the UK have led in the global effort to develop, manufacture and deploy the COVID-19 vaccines, therapies and diagnostics needed to re-open the global economy. As the Prime Minister made clear last week, this successful public-private partnership is the formula for our country’s prosperity for years to come, a strong and active government investing massively in science and technology, coupled with a dynamic enterprise economy.

BIA welcomes the establishment of Advanced Research and Invention Agency (ARIA)

Responding to the Government’s announcement of ARIA today, Ruth McKernan CBE, Chair of the BIA Board and Venture Partner at SV Health Investors said:

Dr David Atkins joins the National Genomics Board as the BIA SME representative

Dr David Atkins, Chief Executive Officer of Congenica, has joined the National Genomics Board as the BioIndustry Association (BIA)’s SME representative. The Board brings together senior decision makers from government, the NHS, academia and industry to advise the UK Government on its national genomics strategy, Genome UK. Dr Atkins’ appointment to the Board means that the voice of genomic start-ups and SMEs will be heard at the highest levels of government.

BIA reacts to the UK hitting the 15 million vaccination target

Steve Bates OBE, Chief Executive of the BIA said: “This fantastic news is down to the strong triple helix partnership between industry, academia and government that has developed through COVID-19 vaccine work, where the UK industry began in February 2020 to understand how we could manufacture and scale up a successful COVID-19 vaccine. The foresight and leadership of Kate Bingham was pivotal in securing these vaccines last summer, giving the NHS and PHE critical lead in time to understand how to deploy these complex products.

BIA and ABPI joint statement on Michael Gove letter to EU

Our industry welcomes the proposal by the UK government to extend the arrangements on medicines in Northern Ireland agreed last December for a further year at least until 1 January 2023

BIA reacts to largest acquisition of a UK biotech company on record as Jazz Pharmaceuticals purchases GW Pharma for $7billion

Reacting to news that GW Pharma will be acquired by Jazz Pharmaceuticals for $7billion,

BIA reacts to Abingworth announcement of new life sciences fund – Abingworth Bioventures 8

Oversubscribed transatlantic fund to invest in US, UK and European life science companies developing innovative therapeutics with potential to significantly improve human health

UK Biotech success continues as sector secures a record year of investment in 2020

New data published today by the UK BioIndustry Association (BIA) and Clarivate PLC reveals that UK biotech companies raised a record £2.8 billion in equity finance in 2020. The science of success: UK biotech in 2020, marks the best year for biotech investments ever recorded by the trade association and shows that since 2012 investment has increased by over 1000%.

BIA reacts to Novavax COVID-19 Vaccine showing 89.3% Efficacy in UK Phase 3 Trial

Steve Bates OBE, Chief Executive of the BIA said: “This is an incredibly important development for the UK and the world in being able to tackle COVID-19. This announcement is down to the foresight and planning of the UK Government Vaccine Taskforce (VTF) with the UK playing a crucial role in the Novavax global clinical trial, with more than 15,000 UK citizens participating. 

BIA welcomes announcement by Health Secretary that UK genomic capacity will support global fight against COVID-19 variants

Today Matt Hancock MP, Secretary of State for Health and Social Care, announced that the UK will offer its genomic capacity to sequence the full genetic code of the COVID-19 virus to scientists and governments around the world.